Debiopharm Group

Raidium is a Medtech startup that is developing the first-ever radiological foundation model, as the “GPT-4” of radiology. This new generation of AI will enable the building of an imaging biomarker factory for both clinical practice and research, to tackle the complexity of precision medicine.

Tune Insight specializes in data security software that enables secure collaborations on sensitive data among multiple organizations. The company's innovative platform employs advanced analytics, privacy measures, and encryption technologies to facilitate federated learning, allowing organizations to collaboratively extract insights while maintaining control over their data. By fostering a secure environment for data sharing, Tune Insight helps organizations make informed decisions together, leveraging collective intelligence without compromising data privacy.

WhiteLab Genomics is a biotechnology company that has developed a proprietary platform utilizing graph knowledge technology and machine learning to support the discovery and design of new genomic therapies. By providing a comprehensive database, the platform allows scientists to conduct detailed analyses of various datasets, facilitating solutions to critical scientific and technical challenges. These include optimizing plasmid and vector design, assessing genotoxicity, and identifying effective experimental protocols for both in vivo and in vitro applications. WhiteLab Genomics focuses on guiding clients through the in-silico development phases, enabling them to efficiently create target vectors and payloads. This streamlined approach not only saves time but also accelerates the delivery of innovative genomic therapies to patients.

Novadiscovery SAS, established in 2010 and located in Lyon, France, specializes in the development of Jinko, an in silico clinical trial simulation platform. This innovative platform assists pharmaceutical and biotechnology companies in conducting virtual trials, allowing them to predict the clinical benefits of new drugs prior to human testing. Jinko focuses on various therapeutic areas, including immuno-oncology, orphan diseases, metabolic diseases, and cardiotherapy. By utilizing advanced mathematics and intelligent algorithms, Novadiscovery creates a community of virtual patients, enabling researchers to optimize drug discovery processes, reduce risks, and minimize costs associated with bringing new drugs to market.

Little Green House operates a chain of educational centers dedicated to enhancing children's cognitive abilities while prioritizing their emotional well-being and social skills. The organization aims to create an inclusive environment where children can express themselves freely and pursue their individual growth. Its centers offer diverse developmental activities, including play areas, site visits, and opportunities for learning musical instruments, all designed to foster the holistic development of children. Through these initiatives, Little Green House seeks to support the overall growth and development of young learners in a nurturing atmosphere.

Coorpacademy S.A. is a Swiss company based in Lausanne, established in 2013. It specializes in developing online training courses and innovative learning solutions, including MOOCs. The company offers a learning experience platform that features a diverse catalog of training courses, which are designed to provide short, accessible sessions that users can engage with at any time and on various devices. This platform aims to revolutionize digital learning for employees by delivering customized content tailored to individual needs. Coorpacademy was founded by Frederick Benichou, Jean-Marc Tassetto, and Arnauld Mitre.

Immunexpress Pty Ltd is a molecular diagnostics company based in Brisbane, Australia, with an additional office in Seattle, Washington. Founded in 2006, the company specializes in developing clinical assays aimed at the early detection and management of sepsis, particularly in patients at risk. Immunexpress focuses on the discovery and clinical validation of genomic and proteomic biomarkers, translating these findings into diagnostic and monitoring assays suitable for point-of-care applications. Its key products include SeptiCyte Triage, designed for screening sepsis in emergency and intensive care units; SeptiCyte STAT, which monitors high-risk patients in ICUs and post-operative wards; and SeptiCyte RTT, a tool for assessing the immune status of ICU patients with sepsis. The approach taken by Immunexpress utilizes blood gene expression to quantify the immune response to pathogens, moving away from traditional methods that seek to identify the causative pathogen.

GenePOC Inc. is a privately owned company, member of Debiopharm Group, that develops accurate and cost-effective molecular solutions to detect pathogen genes. GenePOC has developed a simple and stand-alone system for the prevention and early detection of infectious diseases based on a unique microfluidic technology.

Coorpacademy S.A. is a Swiss company based in Lausanne, established in 2013. It specializes in developing online training courses and innovative learning solutions, including MOOCs. The company offers a learning experience platform that features a diverse catalog of training courses, which are designed to provide short, accessible sessions that users can engage with at any time and on various devices. This platform aims to revolutionize digital learning for employees by delivering customized content tailored to individual needs. Coorpacademy was founded by Frederick Benichou, Jean-Marc Tassetto, and Arnauld Mitre.

Immunexpress Pty Ltd is a molecular diagnostics company based in Brisbane, Australia, with an additional office in Seattle, Washington. Founded in 2006, the company specializes in developing clinical assays aimed at the early detection and management of sepsis, particularly in patients at risk. Immunexpress focuses on the discovery and clinical validation of genomic and proteomic biomarkers, translating these findings into diagnostic and monitoring assays suitable for point-of-care applications. Its key products include SeptiCyte Triage, designed for screening sepsis in emergency and intensive care units; SeptiCyte STAT, which monitors high-risk patients in ICUs and post-operative wards; and SeptiCyte RTT, a tool for assessing the immune status of ICU patients with sepsis. The approach taken by Immunexpress utilizes blood gene expression to quantify the immune response to pathogens, moving away from traditional methods that seek to identify the causative pathogen.

Immunexpress Pty Ltd is a molecular diagnostics company based in Brisbane, Australia, with an additional office in Seattle, Washington. Founded in 2006, the company specializes in developing clinical assays aimed at the early detection and management of sepsis, particularly in patients at risk. Immunexpress focuses on the discovery and clinical validation of genomic and proteomic biomarkers, translating these findings into diagnostic and monitoring assays suitable for point-of-care applications. Its key products include SeptiCyte Triage, designed for screening sepsis in emergency and intensive care units; SeptiCyte STAT, which monitors high-risk patients in ICUs and post-operative wards; and SeptiCyte RTT, a tool for assessing the immune status of ICU patients with sepsis. The approach taken by Immunexpress utilizes blood gene expression to quantify the immune response to pathogens, moving away from traditional methods that seek to identify the causative pathogen.

Affinium Pharmaceuticals is a specialty pharmaceutical company dedicated to developing innovative anti-infective medications. The company focuses on its FASII antibacterial programs, which represent a new franchise of antibiotics targeting the FASII pathway. These programs are supported by a robust portfolio of intellectual property, including both issued and pending patents for potent orally available small molecule inhibitors. Affinium's unique approach aims to address the growing need for effective antibiotics by targeting an underexploited mechanism of action, positioning the company at the forefront of the fight against resistant infections.

BPA Solutions SA specializes in providing innovative business applications that enhance Microsoft SharePoint and Office 365. Founded in 2001 and headquartered in Yverdon-les-Bains, Switzerland, the company develops a range of solutions including BPA CRM for customer relationship management, BPA Quality for quality management, and BPA Risk for tracking business activities in complex environments. Additional offerings include BPA Project for project management, BPA Recruiting for candidate management, and Self-Service tools for process sharing. BPA Solutions also features a Solutions Suite to monitor critical business processes and mobile solutions, along with professional services such as training, consulting, and support. The company delivers its software on-premise, through private or Microsoft clouds, and in hybrid environments, serving clients globally.

Skioo is a company dedicated to enhancing the skiing experience by providing a seamless platform for ski ticketing and adventure booking. The Skioo Pass offers skiers instant access to an extensive network of partner resorts in Switzerland and beyond. By integrating with the systems of ski resorts, ski-lift operators, and online accommodation platforms, Skioo simplifies the booking process for users, allowing them to purchase ski tickets from a single interface. Additionally, the Skioo App fosters a community of skiing enthusiasts and provides valuable information and features to enrich the skiing experience. Founded in 2019 as part of Skitude, Skioo is driven by a team of outdoor enthusiasts and collaborates with notable technology partners to deliver its services effectively.

Urturn is the new social platform for self-expression. Both on the Desktop and as an iPhone app, users are able to spontaneously capture moments of inspiration on-the-fly! The ever-growing library of Expression can be instantly personalised in all kinds of ways and the unique 'Your Turn' button lets users take inspiration from or join in with online movements in rich and interactive way. Spontaneous, engaging and fun, Urturn is the next natural step for social media. It's Urturn...

Compliant Concept AG, based in Dübendorf, Switzerland, specializes in developing advanced bed systems aimed at the treatment and prevention of pressure ulcers. Founded in 2009 as a spinoff from the Empa and ETH Zurich, the company leverages technology to enhance patient care in hospitals and nursing homes. Its intelligent bed systems incorporate mobility monitors that assess clinical risks and identify factors influencing pressure ulcer development, such as medication and pre-bedtime activities. By automating routine tasks, Compliant Concept's solutions help reduce the workload of healthcare professionals, allowing them to focus on providing better care to patients while improving overall comfort and efficiency in healthcare settings.

Spinomix is a Swiss technology platform company based at the Ecole Polytechnique Fédérale de Lausanne (EPFL), specializing in innovative sample processing solutions for the life sciences sector. The company aims to establish a new standard for the processing of biochemical substances, enhancing the quality and efficiency of sample capture and extraction, which is crucial for accurate diagnostics in various human diseases. Spinomix's flagship products, MagPhase™ and FibroTrap™, significantly improve the analysis of complex samples such as blood, urine, and food matrices, which are often challenging to process. The company recognizes the labor-intensive nature of current sample processing methods and sees a substantial opportunity to streamline these processes. Spinomix targets key growth markets, including nucleic acids extraction, cell separation, food safety, and molecular diagnostics for infectious diseases. By focusing on product innovation and market validation, Spinomix is building collaboration agreements with industry leaders to validate its technologies and develop strategic commercial partnerships for licensing its products.

Biocartis SA, established in 2007 and headquartered in Lausanne, Switzerland, is a molecular diagnostics company specializing in developing diagnostic technology platforms for multiplexed detection of bio-analytes such as proteins, nucleic acids, and small molecules. The company focuses on integrated molecular and immunodiagnostics using its proprietary micro-technology platform, offering products like the Idylla system for oncology and infectious disease segments. These products aid in early detection, staging, treatment selection, and monitoring of diseases by analyzing bio-molecules associated with risk factors. Biocartis generates revenue primarily through product sales.

Skioo is a company dedicated to enhancing the skiing experience by providing a seamless platform for ski ticketing and adventure booking. The Skioo Pass offers skiers instant access to an extensive network of partner resorts in Switzerland and beyond. By integrating with the systems of ski resorts, ski-lift operators, and online accommodation platforms, Skioo simplifies the booking process for users, allowing them to purchase ski tickets from a single interface. Additionally, the Skioo App fosters a community of skiing enthusiasts and provides valuable information and features to enrich the skiing experience. Founded in 2019 as part of Skitude, Skioo is driven by a team of outdoor enthusiasts and collaborates with notable technology partners to deliver its services effectively.

Tweasy is a company that offers an online marketing platform designed to assist small businesses, clubs, and associations in enhancing their customer engagement. The Tweasy application consolidates news, promotions, surveys, and various information generated by these organizations, facilitating effective communication with their clientele. By leveraging a cloud-based and Software as a Service (SaaS) model, Tweasy enables its users to implement local, social, and mobile marketing strategies, thereby fostering strong and profitable relationships with their customers.

Immunexpress Pty Ltd is a molecular diagnostics company based in Brisbane, Australia, with an additional office in Seattle, Washington. Founded in 2006, the company specializes in developing clinical assays aimed at the early detection and management of sepsis, particularly in patients at risk. Immunexpress focuses on the discovery and clinical validation of genomic and proteomic biomarkers, translating these findings into diagnostic and monitoring assays suitable for point-of-care applications. Its key products include SeptiCyte Triage, designed for screening sepsis in emergency and intensive care units; SeptiCyte STAT, which monitors high-risk patients in ICUs and post-operative wards; and SeptiCyte RTT, a tool for assessing the immune status of ICU patients with sepsis. The approach taken by Immunexpress utilizes blood gene expression to quantify the immune response to pathogens, moving away from traditional methods that seek to identify the causative pathogen.

Agendia, Inc. is a biotechnology company based in Irvine, California, founded in 2003. The company specializes in developing and distributing genomic-based diagnostic kits aimed at improving cancer treatment for patients. Agendia's molecular diagnostic technology offers insights into a patient's genomic profile, allowing physicians to make informed decisions regarding personalized treatment plans. The company's breast cancer tests utilize a comprehensive analysis of the human genome to evaluate individual risks for metastasis and determine the most appropriate therapies. This includes identifying which patients would benefit from chemotherapy or hormonal treatments, as well as those who may avoid more aggressive interventions in favor of less intensive and cost-effective options.

Biocartis SA, established in 2007 and headquartered in Lausanne, Switzerland, is a molecular diagnostics company specializing in developing diagnostic technology platforms for multiplexed detection of bio-analytes such as proteins, nucleic acids, and small molecules. The company focuses on integrated molecular and immunodiagnostics using its proprietary micro-technology platform, offering products like the Idylla system for oncology and infectious disease segments. These products aid in early detection, staging, treatment selection, and monitoring of diseases by analyzing bio-molecules associated with risk factors. Biocartis generates revenue primarily through product sales.

Biocartis SA, established in 2007 and headquartered in Lausanne, Switzerland, is a molecular diagnostics company specializing in developing diagnostic technology platforms for multiplexed detection of bio-analytes such as proteins, nucleic acids, and small molecules. The company focuses on integrated molecular and immunodiagnostics using its proprietary micro-technology platform, offering products like the Idylla system for oncology and infectious disease segments. These products aid in early detection, staging, treatment selection, and monitoring of diseases by analyzing bio-molecules associated with risk factors. Biocartis generates revenue primarily through product sales.

Curis, Inc. is a biotechnology company focused on the discovery and development of innovative drug candidates for the treatment of various human cancers. Based in Lexington, Massachusetts, the company is advancing several clinical-stage candidates, including CA-4948, an oral small molecule currently undergoing Phase I trials for non-Hodgkin lymphomas and acute myeloid leukemia. Other notable candidates in its pipeline include CI-8993, a monoclonal antibody targeting T cell activation, and Fimepinostat, a dual inhibitor for MYC-altered diffuse large B-cell lymphoma. Additionally, Curis is developing CA-170 for advanced solid tumors and CA-327, which is in pre-investigational stages. The company has established collaborations with leading organizations, including F. Hoffmann-La Roche and Genentech for the commercialization of Erivedge, a treatment for advanced basal cell carcinoma, and Aurigene Discovery Technologies for advancing small molecule compounds in immuno-oncology and precision oncology. Curis aims to leverage its expertise in signaling pathway drug technologies to create targeted therapies that address unmet medical needs in cancer treatment.